Septodont
Paris, France, March 19, 2025 – Septodont, the world leader in dental anesthesia and leading manufacturer of dental pharmaceuticals and medical devices, is announcing a change in its governance structure. Effective June 2nd, 2025, Karim Khadr will be appointed Chief Executive Officer (CEO). Karim Khadr will succeed Olivier Schiller who will continue to serve the company as Chairman of the Board.
Paris, France, March 19, 2025 – Septodont, the world leader in dental anesthesia and leading manufacturer of dental pharmaceuticals and medical devices, is announcing a change in its governance structure. Effective June 2nd, 2025, Karim Khadr will be appointed Chief Executive Officer (CEO). Karim Khadr will succeed Olivier Schiller who will continue to serve the company as Chairman of the Board.
“This development is a natural next step for our Group and a decision I have made as I approach my 65th birthday”, said Olivier Schiller. “I have worked side by side with Karim since he joined Septodont in 2021 and have experienced first-hand his strategic mindset, his values, and commitment to our employees and our customers. He is a highly accomplished leader, and it is with great confidence that I am handing over my responsibilities as Chief Executive Officer.”
Karim Khadr is a senior executive with over 30 years of experience, serving in various sales, marketing, business development, and product management functions, in both large and small organizations in the medical devices and diagnostics industry. He joined Septodont 4 years ago as Global Dental President in charge of sales, marketing, and innovation.
I am privileged to have been given the opportunity to continue building on the success that Septodont has achieved under Olivier’s exceptional leadership, and I am excited to take on this responsibility starting in June. I look forward to working closely with the management team and all our employees to continue successfully executing on our strategy going forward. ”
Karim Khadr
Today’s announcement marks a time of opportunity for the entire Septodont Group. As Olivier moves into his new seat as Chairman of the Board, he will continue to serve the organization focusing on the company’s long-term growth and providing strategic direction to the board.
Septodont is a leading manufacturer of dental pharmaceuticals and medical devices. Since its inception in 1932, the group develops, produces and distributes a large range of products and solutions dedicated to serving the needs of dental professionals across the world. The group counts 2,300 employees and has a long-established presence in more than 110 countries. Beyond dental and through its Novocol Pharma division, the group also partners with pharmaceutical and medical device companies to provide contract manufacturing services for pharmaceutical products that require cartridge filling. Learn more about Septodont’s innovative products and solutions at https://www.septodontcorp.com/.
Sign up now and get an exclusive access to: